KNE Kane Biotech Inc.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Kane Biotech (CVE: KNE)
›
Kane Biotech (CVE: KNE) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0300 CAD on 19 November 2026, down 25.0% over 52 weeks. Its 52-week range is 0.0150 CAD to 0.0500 CAD: the price is 40.0% below the high and 100.0% above the low.
Its market capitalisation is 6.15M CAD.
Kane Biotech reports return on equity of 364.5% and revenue down 70.9% year over year.
Its debt exceeds its cash by 1.11M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.